Advances in Host-Directed Therapies Against Tuberculosis
portes grátis
Advances in Host-Directed Therapies Against Tuberculosis
Hafner, Richard; Gennaro, Maria Laura; Karakousis, Petros C.
Springer Nature Switzerland AG
12/2021
332
Mole
Inglês
9783030569075
15 a 20 dias
534
Descrição não disponível.
Section 1: Introduction
Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis
Daniel Frank, Robert Mahon
Section 2: Targeting immunometabolism
Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism
Lorissa Smulan, Hardy Kornfeld, and Amit Singhal
Chapter 3: The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells
Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro
Chapter 4: HIF-1? as a potential therapeutic target for tuberculosis treatment
Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi
Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis
Eun-Kyeong Jo
Section 3: Enhancing anti-mycobacterial mechanisms
Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis
Surbhi Verma, Raman Deep Sharma and Dhiraj Kumar
Chapter 7: Metformin: a leading HDT candidate for TB
Amit Singhal and Hardy Kornfeld
Chapter 8: Statins as host-directed therapy for tuberculosis
Noton K. Dutta, Petros C. Karakousis
Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms
Rikesh K Dubey, Apoorva Narain
Section 4: Targeting immune cells
Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis
Paula Ruibal, Tom H.M. Ottenhoff, Simone A. Joosten
Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma
Sadiya Parveen, John R. Murphy, and William R. Bishai
Chapter 12: Targeting suppressor T cells
Leanie Kleynhans, Gerhard Walzl
Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis
Tobias Dallenga, Ulrich E. Schaible
Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis
Katrin D. Mayer-Barber, Christopher M. Sassetti
Chapter 15: Mucosal-associated invariant and V?9V?2 T cells
Charles K. Vorkas, Michael S. Glickman
Chapter 16: Airway epithelial cells
Angelica M. Olmo-Fontanez, Jordi B. Torrelles
Section 5: Preclinical models for assessing HDTs
Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies
Liku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. Elkington
Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis
Pere-Joan Cardona, Cristina Vilaplana
Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis
Selvakumar Subbian, Gilla Kaplan
Section 6: Clinical trials of HDTs and special considerations for study endpoints
Chapter 20: Clinical trials of TB-HDT candidates
Robert S. Wallis
Chapter 21: Outcomes for clinical trials of host-directed therapies for tuberculosis
Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. Bisson
Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis
Elisa H. Ignatius, Kelly E. Dooley
Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis
Daniel Frank, Robert Mahon
Section 2: Targeting immunometabolism
Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism
Lorissa Smulan, Hardy Kornfeld, and Amit Singhal
Chapter 3: The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells
Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro
Chapter 4: HIF-1? as a potential therapeutic target for tuberculosis treatment
Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi
Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis
Eun-Kyeong Jo
Section 3: Enhancing anti-mycobacterial mechanisms
Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis
Surbhi Verma, Raman Deep Sharma and Dhiraj Kumar
Chapter 7: Metformin: a leading HDT candidate for TB
Amit Singhal and Hardy Kornfeld
Chapter 8: Statins as host-directed therapy for tuberculosis
Noton K. Dutta, Petros C. Karakousis
Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms
Rikesh K Dubey, Apoorva Narain
Section 4: Targeting immune cells
Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis
Paula Ruibal, Tom H.M. Ottenhoff, Simone A. Joosten
Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma
Sadiya Parveen, John R. Murphy, and William R. Bishai
Chapter 12: Targeting suppressor T cells
Leanie Kleynhans, Gerhard Walzl
Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis
Tobias Dallenga, Ulrich E. Schaible
Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis
Katrin D. Mayer-Barber, Christopher M. Sassetti
Chapter 15: Mucosal-associated invariant and V?9V?2 T cells
Charles K. Vorkas, Michael S. Glickman
Chapter 16: Airway epithelial cells
Angelica M. Olmo-Fontanez, Jordi B. Torrelles
Section 5: Preclinical models for assessing HDTs
Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies
Liku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. Elkington
Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis
Pere-Joan Cardona, Cristina Vilaplana
Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis
Selvakumar Subbian, Gilla Kaplan
Section 6: Clinical trials of HDTs and special considerations for study endpoints
Chapter 20: Clinical trials of TB-HDT candidates
Robert S. Wallis
Chapter 21: Outcomes for clinical trials of host-directed therapies for tuberculosis
Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. Bisson
Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis
Elisa H. Ignatius, Kelly E. Dooley
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
host-directed therapy;immunometabolism;tuberculosis;immunopathogenesis;immune pathways;inflammation;infectious diseases;pharmacotherapy
Section 1: Introduction
Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis
Daniel Frank, Robert Mahon
Section 2: Targeting immunometabolism
Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism
Lorissa Smulan, Hardy Kornfeld, and Amit Singhal
Chapter 3: The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells
Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro
Chapter 4: HIF-1? as a potential therapeutic target for tuberculosis treatment
Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi
Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis
Eun-Kyeong Jo
Section 3: Enhancing anti-mycobacterial mechanisms
Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis
Surbhi Verma, Raman Deep Sharma and Dhiraj Kumar
Chapter 7: Metformin: a leading HDT candidate for TB
Amit Singhal and Hardy Kornfeld
Chapter 8: Statins as host-directed therapy for tuberculosis
Noton K. Dutta, Petros C. Karakousis
Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms
Rikesh K Dubey, Apoorva Narain
Section 4: Targeting immune cells
Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis
Paula Ruibal, Tom H.M. Ottenhoff, Simone A. Joosten
Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma
Sadiya Parveen, John R. Murphy, and William R. Bishai
Chapter 12: Targeting suppressor T cells
Leanie Kleynhans, Gerhard Walzl
Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis
Tobias Dallenga, Ulrich E. Schaible
Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis
Katrin D. Mayer-Barber, Christopher M. Sassetti
Chapter 15: Mucosal-associated invariant and V?9V?2 T cells
Charles K. Vorkas, Michael S. Glickman
Chapter 16: Airway epithelial cells
Angelica M. Olmo-Fontanez, Jordi B. Torrelles
Section 5: Preclinical models for assessing HDTs
Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies
Liku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. Elkington
Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis
Pere-Joan Cardona, Cristina Vilaplana
Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis
Selvakumar Subbian, Gilla Kaplan
Section 6: Clinical trials of HDTs and special considerations for study endpoints
Chapter 20: Clinical trials of TB-HDT candidates
Robert S. Wallis
Chapter 21: Outcomes for clinical trials of host-directed therapies for tuberculosis
Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. Bisson
Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis
Elisa H. Ignatius, Kelly E. Dooley
Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis
Daniel Frank, Robert Mahon
Section 2: Targeting immunometabolism
Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism
Lorissa Smulan, Hardy Kornfeld, and Amit Singhal
Chapter 3: The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells
Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro
Chapter 4: HIF-1? as a potential therapeutic target for tuberculosis treatment
Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi
Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis
Eun-Kyeong Jo
Section 3: Enhancing anti-mycobacterial mechanisms
Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis
Surbhi Verma, Raman Deep Sharma and Dhiraj Kumar
Chapter 7: Metformin: a leading HDT candidate for TB
Amit Singhal and Hardy Kornfeld
Chapter 8: Statins as host-directed therapy for tuberculosis
Noton K. Dutta, Petros C. Karakousis
Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms
Rikesh K Dubey, Apoorva Narain
Section 4: Targeting immune cells
Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis
Paula Ruibal, Tom H.M. Ottenhoff, Simone A. Joosten
Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma
Sadiya Parveen, John R. Murphy, and William R. Bishai
Chapter 12: Targeting suppressor T cells
Leanie Kleynhans, Gerhard Walzl
Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis
Tobias Dallenga, Ulrich E. Schaible
Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis
Katrin D. Mayer-Barber, Christopher M. Sassetti
Chapter 15: Mucosal-associated invariant and V?9V?2 T cells
Charles K. Vorkas, Michael S. Glickman
Chapter 16: Airway epithelial cells
Angelica M. Olmo-Fontanez, Jordi B. Torrelles
Section 5: Preclinical models for assessing HDTs
Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies
Liku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. Elkington
Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis
Pere-Joan Cardona, Cristina Vilaplana
Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis
Selvakumar Subbian, Gilla Kaplan
Section 6: Clinical trials of HDTs and special considerations for study endpoints
Chapter 20: Clinical trials of TB-HDT candidates
Robert S. Wallis
Chapter 21: Outcomes for clinical trials of host-directed therapies for tuberculosis
Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. Bisson
Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis
Elisa H. Ignatius, Kelly E. Dooley
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
